Sandbox:haytham1: Difference between revisions

VisualWikitext

Latest revision as of 17:16, 16 October 2015

Initial patients evaluation

History
Physical examination
Complete blood count

Staging

Rai Staging System
Binet Staging System

Rai stage 3-4
Binet stage B-C

Rai stage 0-2
Binet stage A

Evaluate patients by cumulative index illness rating scale

Patients managed by observation and close follow-up

Frail patients (CIRS ≥6)

Fit patients (CIRS <6)

Retixumab/obinutuzumab AND chlorambucil

FISH chromosomal analysis

Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion can be found here

Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion can be found here

Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion

First line therapy

Patients older than 70 years of age with poor performance status:

Obinutuzumab AND chlorambucil
Rituximab AND chlorambucil
Bendamustine AND rituximab
Cyclophosphamide AND predinisone ± retixumab
Retixumab
Fludarabinec ± retixumab
Cladrabine
Chlorambucil
Fludarabine AND cyclophosphamide AND rituximab
Fludarabine AND rituximab
Bendamustine ± rituximab
Obinutuzumab AND chlorambucil

Patients younger than 70 years of age with good status performance status:

Fludarabine AND cyclophosphamide AND rituximab
Fludarabine, rituximab
pentostatin, cyclophosphamide, rituximab
Bendamustine ± rituximab
Obinutuzumab + chlorambucil

Refactory/recurrent therapy

Bendamustine + Rituximab

Chlorambucil

Chlorambucil + PredniSONE

Cladribine

Cyclophosphamide/PredniSONE

Cyclophosphamide/PredniSONE + Rituximab

FCR (Fludarabine/Cyclophosphamide + Rituximab)

Fludarabine

FR (Fludarabine + Rituximab)

MethylPREDNISolone (Pulse)

PCR (Pentostatin/Cyclophosphamide + Rituximab)

Rituximab

Immunochemotherapeutic regimens for the management of patients with chromosome 17p deletion

Alemtuzumab + Rituximab

Bendamustine + Rituximab

FCR (Fludarabine/Cyclophosphamide + Rituximab)

FR (Fludarabine + Rituximab)

HDMP (High-Dose Methylprednisolone) + Rituximab

Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion

Bendamustine + Rituximab

Chlorambucil

Chlorambucil + PredniSONE

Cyclophosphamide/PredniSONE

Cyclophosphamide/PredniSONE + Rituximab

FCR (Fludarabine/Cyclophosphamide + Rituximab)

PCR (Pentostatin/Cyclophosphamide + Rituximab)

Reduced-dose FCR (Fludarabine/Cyclophosphamide + Rituximab)

Rituximab

@@ Line 1: / Line 1: @@
-{{familytree/start |summary=PE diagnosis Algorithm.}}
+{{familytree/start |summary=Therapy Algorithm.}}
 {{familytree | | | | | | A02 | | | | | |A02=<div style="width: 10em; padding:0.2em;">'''Initial patients evaluation'''</div>}}
 {{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;">History<br>Physical examination<br>Complete blood count</div>}}
@@ Line 21: / Line 21: @@
 {{familytree | | | | | |!| | | | | | | | | | | | | | | | | }}
 {{familytree | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | }}
-{{familytree | G01 | | G02 | | G03 | | | | | | | | | | | | |G01=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients '''without''' chromosome 17p deletion or chromosome 11q deletion [[#hi|'''here''']]'''</div>|G02=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 17p deletion]]'''</div>|G03=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients '''with''' [[#Chemotherapy|chromosome 11q deletion]]'''</div>}}
+{{familytree | G01 | | G02 | | G03 | | | | | | | | | | | | |G01=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion can be found [[#Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion|'''here''']]'''</div>|G02=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion can be found [[#Immunochemotherapeutic regimens for the management of patients with chromosome 17p deletion|'''here''']]'''</div>|G03=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion can be found [[#Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion|'''here''']]'''</div>}}
-{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }}
-{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }}
-{{familytree | | | | | | | | | R01 | | | | | | | | | | | |R01=<div style="width: 15em; padding:1em;">Patients Age</div>}}
-{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }}
-{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }}
-{{familytree | | | | | | | |,|-|^|-|.| | | | | | | | | | | | |}}
-{{familytree | | | | | | | H01 | | H02 | | | | | | | | | | | |H01=<div style="width: 15em; padding:1em;">Age <70 years</div>|H02=<div style="width: 15em; padding:1em;">Age ≥70 years</div>}}
 {{familytree/end}}
-==chemotherapy==
+===Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion===
-===Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion===
+====First line therapy====
+*'''Patients older than 70 years of age with poor performance status:'''
+:* Obinutuzumab {{and}} chlorambucil
+:* Rituximab {{and}} chlorambucil
+:* Bendamustine {{and}} rituximab
+:* Cyclophosphamide {{and}} predinisone {{withorwithout}} retixumab
+:* Retixumab
+:* Fludarabinec {{withorwithout}} retixumab
+:* Cladrabine
+:* Chlorambucil
+:* Fludarabine {{and}} cyclophosphamide {{and}} rituximab
+:* Fludarabine {{and}} rituximab
+:* Bendamustine {{withorwithout}} rituximab
+:* Obinutuzumab {{and}} chlorambucil
+*'''Patients younger than 70 years of age with good status performance status:'''
+:* Fludarabine {{and}} cyclophosphamide {{and}} rituximab
+:* Fludarabine, rituximab
+:* pentostatin, cyclophosphamide, rituximab
+:* Bendamustine ± rituximab
+:* Obinutuzumab + chlorambucil
+====Refactory/recurrent therapy====
 Bendamustine + Rituximab
@@ Line 57: / Line 72: @@
 Rituximab
-===Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion===
+===Immunochemotherapeutic regimens for the management of patients with chromosome 17p deletion===
 Alemtuzumab + Rituximab

Sandbox:haytham1: Difference between revisions

Latest revision as of 17:16, 16 October 2015

Contents

Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion

First line therapy

Refactory/recurrent therapy

Immunochemotherapeutic regimens for the management of patients with chromosome 17p deletion

Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion

Navigation menu